Corbion
Corbion ferments lactic acid and biobased ingredients for food, pharma, and bioplastics.
On the record
Checkpoint: H1 2026 results, plus resolution of the TotalEnergies Corbion PLA joint-venture stake sale
The call
Corbion's pharma and food-safety business runs on certifications and data that are hard to copy, while its commodity lactic acid and bioplastics arms are being cut loose under Chinese price pressure and activist scrutiny.
Corbion is a Dutch company that uses fermentation (like brewing beer) to make ingredients for medicines, food, and plastics. It has been around 95 years and is profitable. The company is hard to replace in pharma and food safety because it holds special certifications, quality approvals, and data that took years to build, and customers have long-term contracts with it. However, Corbion is stepping away from cheap lactic acid because Chinese competitors can make it for less money, and it is trying to sell its half-ownership of a plastic called PLA to focus on higher-value products. An investor now owns about 10% of the company and is pushing for big changes, which creates uncertainty. The real question is whether Corbion can finish selling its PLA stake and shift to pricier products fast enough before activist pressure or bigger chemical companies like BASF or Evonik try to compete directly.
Why
01
AI pressure: None apparent. This is fermentation chemistry sold under regulatory contracts; no AI product substitutes for cGMP-qualified lactic acid or Listeria control data. Could AI do the core job? Unlikely.
02
Bigger players: Chinese lactic acid producers (Henan Jindan) and NatureWorks/Cargill in bioplastics. Corbion is exiting commodity lactic acid and selling its PLA joint-venture stake after losing ground on price to Chinese producers. Could a giant copy it? Probably.
03
What protects it. USP/EP and cGMP certifications, proprietary Listeria control data, and long-term food-safety and pharma contracts that are costly to re-qualify elsewhere.
What would change this call
Terms and timing of the TotalEnergies Corbion PLA joint-venture stake sale conclude. Weak sale price or delay would confirm bioplastics competitive weakness against Cargill/NatureWorks.
Q2 2026 results (due 30 July 2026) show organic sales growth returning positive or staying negative. Continued decline after Q1's -4.1% would show broader customer or volume loss, not a one-quarter blip.
Inclusive Capital files a proxy proposal or renews its go-private push before the 2027 AGM. Would show activist pressure escalating into a formal contest over Corbion's independence.
Q2 2026 results (due 30 July 2026) show organic sales growth returning positive or staying negative. Continued decline after Q1's -4.1% would show broader customer or volume loss, not a one-quarter blip.
Inclusive Capital files a proxy proposal or renews its go-private push before the 2027 AGM. Would show activist pressure escalating into a formal contest over Corbion's independence.
Key numbers
- FY2025 sales €1,267.4M, EBITDA €204.3M
- Q1 2026 organic sales down 4.1% year on year
- Inclusive Capital activist stake about 10.1%
Named risks
- Activist investor (Inclusive Capital, ~10.1% stake) could push for contested proxy fight or take-private bid.
- Sale of 50% TotalEnergies Corbion PLA joint venture stake, initiated Nov 2025, remains unresolved as of mid-2026.
- Commodity lactic acid segment facing structural erosion from low-cost Chinese producers.
- Pharma segment described by CEO as volatile despite hedging, per Feb 2026 earnings call.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Cargill / NatureWorks LLC | gaining on | Pressure in commodity lactic acid/PLA prompted Corbion's Nov 2025 exit from that segment |
| Henan Jindan Lactic Acid Technology (China) | gaining on | Low-cost Chinese lactic acid production cited as driver of Corbion's portfolio retreat, 2025 |
| BASF, Evonik, DSM-Firmenich, IFF, Kerry Group | contesting | Named adjacent competitors in broader specialty food/materials ingredients space, per 2025-12 market report |
Questions people ask
- Is Corbion profitable in 2025?
- Yes. Corbion reported FY2025 sales of €1,267.4 million (+2.2% organic), Adjusted EBITDA of €204.3 million (+26.7% organic), EPS up 63.3% to €1.29, and free cash flow of €90.8 million, as of 2025-12-31, per its February 2026 results release.
- Is Corbion going private?
- Not confirmed. Activist investor Inclusive Capital (Jeffrey Ubben), holding roughly 10.1% of shares, publicly urged Corbion in December 2023 to explore strategic alternatives including going private; the company responded with restructuring rather than a sale, and no take-private deal has been announced.
- Who is Corbion's biggest competitor?
- In lactic acid and PLA bioplastics, Corbion's named rivals are Cargill, NatureWorks LLC, Galactic, Jungbunzlauer, Futerro, and China's Henan Jindan Lactic Acid Technology; in broader specialty ingredients it competes with BASF, Evonik, DSM-Firmenich, IFF, and Kerry Group.
- Did Corbion lay off workers?
- Yes. In January 2024 Corbion announced a restructuring cutting about 200 jobs, collapsing three business units into two, and closing its fermentation plant in Peoria, Illinois, targeting roughly €55 million in annual cost savings, amid activist pressure.
- Could AI replace Corbion?
- Unlikely soon. Corbion executives (e.g. SVP David J. Charest, per foodingredientsfirst.com, July 2026) use AI internally to analyze fermentation datasets and optimize formulations, but its physical fermentation processes, cGMP/USP-EP pharma certifications, and proprietary Listeria microbiology datasets remain hard for AI models to replicate.
- Is Corbion selling its PLA joint venture?
- Yes, a sale is in progress. At its November 2025 Capital Markets Day, Corbion launched the BRIGHT 2030 strategy and started a formal process to sell its 50% stake in the TotalEnergies Corbion PLA joint venture; the process was still ongoing as of the April 2026 Q1 update.
Timeline
- 2026-07-08TotalEnergies Corbion JV launches Luminy FOAM 50F, a PLA foam replacing polystyrene in food packaging
- 2026-05-13Corbion AGM votes on BRIGHT 2030 targets and 2025 dividend including €0.36/share special dividend
- 2026-04-22Q1 2026 results show -4.1% organic sales decline; FY2026 guidance of +3-6% growth maintained
- 2026-02-26Corbion reports FY2025 sales of €1,267.4M, EBITDA €204.3M (+26.7% organic), EPS €1.29
- 2025-11-20Corbion unveils BRIGHT 2030 strategy and starts formal process to sell 50% PLA joint venture stake
- 2024-04Corbion completes divestiture of Emulsifiers business to Kingswood
- 2024-01-31Corbion announces restructuring: ~200 job cuts, Peoria Illinois plant closure, targeting €55M annual savings
- 2023-12Activist investor Inclusive Capital publicly urges Corbion to explore going private
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Corbion announces strong full-year 2025 results (2026-02-26)
- Corbion Q1 2026 Interim Management Statement (2026-04-22)
- gurufocus.com (2026-07-24)
- Corbion N.V. Insider Trading & Ownership Structure
- Corbion Restructures, Cuts Jobs Amid Activist Call to Go Private (2024-01-31)
- Corbion H1/Q2 2025 press release (2025-07-31)
- Corbion unveils BRIGHT 2030 strategy (2025-11-20)
- Corbion posts jump in earnings in H1 2025 (2026-07-20)
- Corbion Number of Employees 2026 (2026-06-29)
- Corbion Annual Report, Human Capital
- Corbion Annual Report, At a glance
- Capital Markets Day 2025 transcript (2025-11-20)